Clinical trials: Infliximab, active
Rheumatoid Arthritis
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
Rheumatoid arthritis (RA) is a common disease with approximately 1% prevalence. RA is also a chronic, progressive disease with no cure.
- Trial name
- NCT03414502
- Testing
- Methotrexate, Abatacept, Adalimumab
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- University of Nebraska
Ulcerative Colitis (UC)
A Direct Head-to-head Comparison of Ustekinumab With Infliximab for the Treatment of Ulcerative Colitis
the goal of this study is to compare the efficacy of ustekinumab with infliximab for the treatment of ulcerative colitis aim of the study : 1.
- Trial name
- NCT06786507
- Testing
- Ustekinumab 90 mg, Infliximab
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Helwan University
Ulcerative Colitis, Inflammatory Bowel Diseases
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
The goal of this clinical trial is to learn if combined therapy with infliximab and ustekinumab works better than using these drugs alone in adult patients with ulcerative colitis.
- Trial name
- COMBO-UC (NCT06453317)
- Testing
- Infliximab, Ustekinumab
- Where
- Poland
- Volunteers
- 172 people
- Sponsor
- Medical University of Lodz
Crohn Disease
Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
To evaluate the clinical manifestations, treatment options, and improved clinical outcomeof children with Crohn's disease in real-world Settings: (1) analysis of clinical manifestations; (2) probability of using the same…
- Trial name
- CD (NCT06673134)
- Testing
- enteral nutrition, Immunotherapy, biological agents
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
Crohn Disease
Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease
Crohn's disease (CD) is a chronic inflammatory bowel disease with high recurrence and surgical rates. Mucosal healing is a key therapeutic goal, yet current anti-TNF-α biologics achieve only about 30% mucosal healing.
- Trial name
- CDED (NCT07344428)
- Testing
- Crohn's Disease Exclusion Diet
- Where
- China
- Volunteers
- 185 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Ulcerative Colitis
Efficacy of Subcutaneous Infliximab in Acute Severe Ulcerative Colitis: a Multicenter Retrospective Study
Around 25% of patients with ulcerative colitis will develop acute severe colitis during the course of their disease. The first-line treatment for acute severe colitis is intravenous corticosteroid therapy.
- Trial name
- ISAC (NCT06998797)
- Testing
- Data collection
- Volunteers
- 50 people
- Sponsor
- Central Hospital, Nancy, France
Crohn's Disease
Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD
The goal of this prospective, multicenter, open-label, randomized controlled, non-inferiority trial is to test efficacy and safety of formulation switching between subcutaneous (SC) infliximab and intravenous (IV) infliximab in…
- Trial name
- CHAMELEON (NCT06064864)
- Testing
- Infliximab-Dyyb
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Rheumatoid Arthritis, Ankylosing Spondylitis
Korean College of Rheumatology Biologics and Targeted Therapy Registry
We established a nationwide biologics and targeted synthetic DMARDs registry (in the form of an inception cohort) to study the safety profiles in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis patients…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- KOBIO (NCT01965132)
- Testing
- Biologic or targeted synthetic DMARD
- Where
- South Korea
- Volunteers
- 10,000 people
- Sponsor
- Seoul National University Hospital
Aneurysm, Stroke
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
Patients harboring dolichoectactic vertebrobasilar (DVB) aneurysms are at risk of suffering SAH, ischemic stroke, and/or brainstem compression and many patients are not offered invasive treatment due to the futility of existing…
- Conditions
- Aneurysm, Stroke, Vasculitis, Tumor Necrosis Factor-alpha
- Trial name
- NCT02638701
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
Takayasu Arteritis
Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission
Takayasu arteritis is a chronic large-vessel vasculitis affecting the aorta and its major branches. Biologic therapies such as tumor necrosis factor inhibitors and tocilizumab are commonly used in patients with refractory or…
- Trial name
- NCT07491913
- Testing
- Tociliuzumab, Infliximab, Adalimumab
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Inflammatory Disease, Disease Crohn
InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
Study Design: A Prospective Multicenter Randomized Controlled, Open-label Non-inferiority Study to Investigate the Efficacy of Subcutaneous (SC) Infliximab (IFX) with and without Immunomodulators during Induction treatment in…
- Conditions
- Inflammatory Disease, Disease Crohn, Bowel Disease
- Trial name
- DIRECTCD (NCT06059989)
- Testing
- Infliximab subcutaneous, Immunosuppressive Agents
- Where
- Netherlands
- Volunteers
- 158 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Crohn Disease (CD)
TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response
This multicenter, randomized, controlled trial aims to evaluate the efficacy and safety of standard-dose tumor necrosis factor inhibitor (TNFi) plus low-dose upadacitinib compared with TNFi dose intensification in patients with…
- Trial name
- CD (NCT07510191)
- Testing
- Upadacitinib, Infliximab Dose Intensification, Adalimumab Dose Intensification
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Inflamatory Bowel Disease, Crohn Disease (CD)
Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
This retrospective cohort study aims to compare the efficacy of different biologics in preventing postoperative endoscopic recurrence in Crohn's disease (CD).
- Trial name
- NCT07694674
- Testing
- Infliximab, Adalimumab, Vedolizumab
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Shanghai 10th People's Hospital
Ulcerative Colitis (UC), Crohn's Disease (CD)
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals…
- Conditions
- Ulcerative Colitis (UC), Crohn's Disease (CD), Indeterminate Colitis, Inflammatory Bowel Disease (IBD)
- Trial name
- ZEST (NCT07237516)
- Where
- 11 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of North Carolina, Chapel Hill
Crohn Disease
Precise Infliximab Exposure and Pharmacodynamic Control
Approximately 3 million people in the United States are living with inflammatory bowel disease, which includes Crohn's Disease (CD).
- Trial name
- REMODEL-CD (NCT05660746)
- Testing
- RoadMAB, Infliximab
- Where
- 11 sites in United States
- Volunteers
- 180 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Crohn Disease, Infliximab
Combined Immunosuppression for Pediatric Crohn's Disease
This is a randomized controlled trial to compare the efficacy and safety of infliximab and immunosuppressives therapy alone or in combination for pediatric Crohn's disease.
- Conditions
- Crohn Disease, Infliximab, Immunosuppression, Children, Only
- Trial name
- NCT05043870
- Testing
- Infliximab and immunosuppressives, Infliximab
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Children's Hospital of Fudan University
Acute Severe Ulcerative Colitis
Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO Trial
In adults hospitalized with acute severe ulcerative colitis who fail to respond to intravenous steroids, does treatment with a combination of infliximab and tofacitinib, compared with infliximab alone or tofacitinib alone, result…
- Trial name
- NCT07297069
- Testing
- Infliximab, Tofacitinib
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Asian Institute of Gastroenterology, India
Crohn's Disease (CD)
Biologics and Paediatric Enteral Nutrition in Crohn's Disease Study
Crohn's disease (CD) is a chronic, incurable condition associated with gut inflammation. Two important treatments currently used to manage CD are special drug injections (biologics) or a liquid-only diet using specialised…
- Trial name
- BIOPIC-Kids (NCT07522528)
- Testing
- enteral nutrition
- Where
- 6 sites in United Kingdom
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Inflammatory Bowel Diseases, Crohn Disease
De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease
BACKGROUND/RATIONALE: Treatment outcomes of patients with inflammatory bowel disease (IBD) have improved enormously during the past decade due to the use of anti-tumour necrosis factor (anti-TNF) therapy.
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative
- Trial name
- FREE (NCT04646187)
- Testing
- Infliximab, Adalimumab
- Where
- 7 sites in Belgium, Netherlands and 1 more
- Volunteers
- 148 people
- Sponsor
- University Medical Center Groningen
Inflammatory Bowel Disease (IBD), Crohn Disease (CD)
PROactive and Early Infliximab Monitoring and OPTimization in Inflammatory Bowel Disease
Infliximab (IFX) is a Food and Drug administration (FDA)-appoved monoclonal antibody medication targeting tumor necrosis factor (TNF) widely used in inflammatory bowel disease (IBD) to treat intestinal inflammation and improve…
- Conditions
- Inflammatory Bowel Disease (IBD), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PROMPT-IBD (NCT06758024)
- Testing
- Infliximab
- Where
- Chile
- Volunteers
- 72 people
- Sponsor
- Pontificia Universidad Catolica de Chile